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Abstract
Insulin, discovered in 1921 by nicolae paulescu,  and adiponectin, discovered in 1995 
by yuji matsuzawa’s and two other groups, are two important molecules related to the 
maintenance of human energy homeostasis. The close relationship of these two hor-
mones in the development of metabolic pathology (obesity, metabolic syndrome, type 
2 diabetes mellitus) prompted us to use a bioinformatic approach in order to better 
understand the architecture of their gene promoters. In this study, a comprehensive 
analysis was undertaken for adiponectin (aDIpOQ) and insulin (Ins) gene promoter se-
quences from 7 species. In our approach we used 14 promoter sequences (7 promoters 
for each gene) from homologene (ncbI). In order to examine the structural particulari-
ties of aDIpOQ and Ins gene promoters, we used two-dimensional image-based pat-
terns obtained through kappa Index of coincidence (kappa Ic) and (c+g)% values. We 
observed that c+g content variations of aDIpOQ promoter correlates with body mass, 
whereas high kappa Ic values of the Ins gene promoter appear to be correlated with 
brain size.
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introduction
In our society, obesity is a direct con-
sequence of lifestyle, environmental 
exposuers, and genetic predispostion 
(1-3). It is currently associated with 
a considerable number of pathologi-
cal conditions, such as type 2 diabetes 
mellitus (T2DM), cardiovascular dis-
ease, arthritis and other various com-
plications (1,4). 
Adipose tissue is the major „ware-
house” for triglycerides and a main 
link in the energy balance mecha-
nism. Generally, adipose tissue mass 
increases when energy intake exceeds 
energy consumption. Thus, the adi-
pose tissue stands to be as an active 
and dynamic endocrine subsystem 
that produces a number of signaling 
proteins known as adipokines, which 
affect the function of adjacent and/
or distant organs in health and dis-
ease (5-8). Examples of „the rapidly 
expanding family of adipokines” (9) 
include adipsin, leptin, adiponectin, 
apelin, chemerin, interleukin-6 (IL-6), 
IL-10,  plasminogen activator inhibi-
tor-1 (PAI-1), retinol-binding protein 
4 (RBP4), tumor necrosis factor-alpha 
(TNF-α) and visfatin (8-10). The most 
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abundant adipokine is adiponectin (a relatively large 244-ami-
no-acid-long polypeptide) which is found in human serum at 
high concentrations (between 2-20 μg/mL) and is inversely cor-
related with body mass index (BMI), T2DM, atherogensis and 
cancerogensis (11-15). In the bloodstream, adiponectin circu-
lates in diff erent forms, such as trimeric, hexameric and higher 
order complexes (16).  Adiponectin treatment is able to counter-
act T2DM and atherosclerosis as well as other pathological states 
(17-25).  Compared to normal individuals in which adiponectin 
is inversely related to glucose and insulin, the obese patients ex-
hibit decreased concentrations of adiponectin (26,27). We sug-
gest that an overview from an evolutionary perspective of insu-
lin and adiponectin may open new avenues for addressing the 
issues in both obesity and T2DM. 
In the present study, we tried to observe two correlations in 
several species: (i) between body mass (not to be confused with 
BMI) and ADIPOQ gene promoters, and (ii) between brain 
mass and INS gene promoters. In order to understand their cor-
relation at the genetic level, we used our own original method 
based on Kappa index of coincidence, as previously published 
(28).
In our approach we used 14 promoter sequences (7 promot-
ers for each gene) from HomoloGene (29). We used 500 bases 
upstream of ADIPOQ gene and INS gene from Homo sapiens 
(NT_005612.16), P. troglodytes (NW_003456895.1), C. lupus 
(NW_003726120.1), B. taurus (NW_003103812.1), M. musculus 
(NW_003103812.1), R. norvegicus (NW_047356.1) and G. gal-
lus (NW_001471743.2). We used Visual Basic to develop a soft -
ware program for promoter analysis - called PromKappa (Fig. 
1). In this method we have used sliding window approach for 
reading two types of values: Kappa IC and (C+G)%.
We observed that C+G content variations of ADIPOQ pro-
moter seem to be correlated with body mass. On the other hand, 
high Kappa IC values of INS gene promoter appear to be cor-
related with brain size. In this case, high Kappa IC values are 
caused by long C+G based homopolymers. Th us the correlation 
Figure 1. prom kappa software (promoter analysis by kappa).
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Figure 2. promoter patterns of aDIpOQ and Ins gene promot-
ers. Each promoter pattern is composed of vertically aligned 
clusters of kappa Ic (y-axis) and gc% (x-axis) values. The cen-
ter of weight for each pattern is represented by a black circle. 
both values  have a range between 1 and 100.
is made between long C+G based homopolymers and brain size 
(Fig. 2). Moreover, from a genetic point of view, one of the ge-
nome areas associated with susceptibility for T2DM includes 
adiponectin (30,31). Several missense mutations of adiponectin 
are also associated with T2DM (32,33). Clinically, adiponectin 
serum levels are reduced in obese or T2DM patients and are es-
pecially low in obese individuals with high visceral fat content 
(34-36). Furthermore, it was observed that anti-diabetic drugs 
cause an increase in adiponectin levels (37). Adiponectin recep-
tors (Adip-R1 and Adip-R2) were found to be expressed in the 
proopiomelanocortin and neuropeptide tyrosine (NPY) neu-
rons in the arcuate nucleus, thus, linking adiponectin to an even 
more active role in the central regulation of energy intake and 
consumption (38).
Interestingly, some studies suggest that T2DM in octogenar-
ians is associated with decreased low molecular weight of adi-
ponectin (39). Adiponectin molecules self-associate into larger 
structures. In this process of self-association, three adiponectin 
molecules bind together to form a trimer, units that continue 
to self-associate in hexamers or dodecamers (40). In human se-
rum, the relative levels of adiponectin higher-order structures 
(high-molecular weight forms) seem to be increased in females. 
In relation to glucose homeostasis, the high-molecular weight 
form of adiponectin appears to be more biologically active and 
was associated with a lower risk of T2DM (41,42).
Other studies link obesity (through low adiponectin levels) 
to an elevated risk of breast, colorectal or prostate cancer (43-
46). Also, adiponectin can reduce cell migration and invasion in 
cancer (47). Nevertheless, the biochemical mechanisms behind 
the action of adiponectin in cancer prevention are unknown. Al-
though the benefi cial implications of adiponectin start getting 
increasingly clearer, the clinical trials regarding an adiponectin 
therapy in humans has yet to be expected. Th e administration 
of adiponectin in mouse has already shown promising eff ects 
(48-50). 
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Conclusion
The role of adiponectin in developing T2DM prompted many 
studies over the last 10 years. In this paper, a comprehensive anal-
ysis was undertaken for ADIPOQ and INS promoter sequences 
from 7 species. In our approach we used 14 promoter sequences 
(7 promoters for each gene) from HomoloGene (NCBI). In order 
to examine the structural particularities of ADIPOQ and INS 
gene promoters, we used two-dimensional image-based patterns 
obtained through Kappa Index of Coincidence (Kappa IC) and 
(C+G)% values. In our analysis we observed that C+G content 
variations of ADIPOQ promoter correlates with body mass. On 
the other hand, high Kappa IC values of INS gene promoter ap-
pear to be correlated with brain size. Our data also suggests that 
C+G content variations of ADIPOQ promoter correlates with 
body mass. How interaction between insulin and adiponectin 
could explain the actual cardiometabolic pathologies remains to 
be Danced round using metabolomic, interactomic and genomic 
approaches.
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